Opinion|Videos|July 15, 2024
Treatment Decision Making in first-line combinations for advanced RCC
Author(s)Martin H. Voss, MD, Moshe Ornstein, MD
The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit.
Advertisement
Episodes in this series
- What are the available first-line combination options for advanced RCC?
- Please discuss your rationale for choosing between IO+IO and IO+TKI approaches and review these data: Network meta-analysis (NMA) –
Grunwald, et al. ASCO GU 2024. Abstract 482 – len + pembro vs other 1L treatments in advanced RCC
- Please discuss your rationale for choosing between IO+IO and IO+TKI approaches and review these data: Network meta-analysis (NMA) –
- How do you approach treatment selection in the frontline setting?
- What factors do you consider when choosing treatment?
- Which patients do you choose len-pembro versus axi-pembro versus cabo-nivo?
Advertisement
Related to this article
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
Premal H. Thaker, MD, MS, discusses INCB123667 in ovarian cancer and the ongoing MAESTRA 2 study.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma
2
Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia
3
Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer
4
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
5